

Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 8, 26 | Nault Casey M. | officer: EVP, GC & Secretary | S-Sale | 10,000 @ $21.06 | $210.6K |
| Aug 19, 26 | Thompson J Kenneth | director | S-Sale | 25,000 @ $20.77 | $519.3K |
| Aug 19, 26 | Nault Casey M. | officer: EVP, GC & Secretary | S-Sale | 10,000 @ $20.00 | $200.0K |
| Aug 19, 26 | Whelan Thomas S | officer: EVP & CFO | S-Sale | 6,000 @ $20.87 | $125.2K |
| Aug 10, 26 | Beckelheimer Dorothy Anne | officer: SVP, Tax Corp Controller CAO | 0 | — | |
| Jun 12, 26 | Mcgrath Aoife | officer: EVP, Exploration | P-Purchase | 635 @ $16.95 | $10.76K |
| Jun 1, 26 | Watkinson Kenneth J | officer: VP, Corporate Controller & CAO | S-Sale | 39,000 @ $18.60 | $725.4K |
| Mar 20, 26 | Schonberner Marilyn Joy | director | A-Award | 4,103 | — |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 23.75 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 7.35 | Oscillator | Buy |
| Williams %R (14) | -93.32 | Oscillator | Buy |
| MACD (12, 26, 9) | -1.24 (Hist -0.22) | Oscillator | Strong Sell |
| Average Directional Index (14) | 28.48 (+DI 15.6 / -DI 40.2) | Trend | Strong Sell |
Stock news · updated daily
AstraZeneca today announced the US availability of ZEGFROVYÂ (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lun
ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast CancerPR NewswireSHANGHAI, O
| EMA 20 | 16.14 | MA | Strong Sell |
| SMA 20 | 16.25 | MA | Strong Sell |
| EMA 50 | 17.41 | MA | Strong Sell |
| SMA 50 | 18.72 | MA | Strong Sell |
| SMA 200 | 19.08 | MA | Strong Sell |
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | 0.26 | 0.12 | Miss -53.5% | $1.09B |
| May 6, 2026 | 0.37 | 0.36 | Miss -1.8% | $856.2M |
| Feb 18, 2026 | 0.39 | 0.35 | Miss -10.3% | $674.8M |
| Oct 29, 2025 | 0.25 | 0.23 | Miss -8.0% | $554.6M |
| Aug 6, 2025 | 0.18 | 0.20 | Beat 11.1% | $480.6M |
| May 7, 2025 | 0.02 | 0.11 | Beat 450.0% | $360.1M |
Annual filings (FY) with consensus forward estimates (hatched)
TTM vs. 5-year historical average (annual ratios)
| Metric | CDE | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 10.7x | -0.8x · sector 16.6x | Discount |
| Forward P/E (FY26E) | 13.5x | EPS est. 1.00 | Elevated |
| Price / Book | 1.3x | 1.8x | Discount |
| Price / Sales | 4.4x | 2.3x | Elevated |
| EV / EBITDA | 8.5x | 15.2x | Discount |
| Return on equity | 12.5% | — | Healthy |
| Gross margin | 50.4% | 29.3% | Above hist. |
| Debt / Equity | 0.07 | 0.48 | Conservative |
| Piotroski / Altman Z | 5/9 | Z 2.15 | Grey zone |
Discounted cash flow model
Current price $13.45
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 7, 26 | Scotiabank | maintain | Sector Outperform | Sector Outperform |
| Jul 14, 26 | Scotiabank | maintain | Sector Outperform | Sector Outperform |
| Apr 29, 26 | Canaccord Genuity | upgrade | Hold | Buy |
| Feb 20, 26 | Canaccord Genuity | downgrade | Buy | Hold |
| Feb 12, 26 | RBC Capital | maintain | Outperform | Outperform |
| Dec 15, 25 | Roth Capital | maintain | Buy | Buy |
| Nov 11, 25 | TD Securities | maintain | Buy | Buy |
| Aug 7, 25 | BMO Capital | maintain | Outperform | Outperform |
| Jul 1, 25 | Roth Capital | maintain | Buy | Buy |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Sep 28, 2026 | 2026-09-28 06:57:59 | View |
| SD | Sep 25, 2026 | 2026-09-25 16:34:10 | View |
| 4 | Sep 9, 2026 | 2026-09-09 16:59:40 | View |
| 4 | Aug 20, 2026 | 2026-08-20 18:30:53 | View |
| 4 | Aug 20, 2026 | 2026-08-20 18:29:53 | View |
| 4 | Aug 20, 2026 | 2026-08-20 18:28:28 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 16:07:20 | View |
| 3 | Aug 11, 2026 | 2026-08-11 17:46:54 | View |
| 8-K | Aug 5, 2026 | 2026-08-05 16:44:15 | View |
| 10-Q | Aug 5, 2026 | 2026-08-05 16:43:07 | View |
Proxy statement (DEF 14A) disclosures
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure